Daiichi Sankyo Germany

Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1502285060HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

Daiichi Sankyo Germany

Germany

Address: Ganghoferstraße 70a
80339 München

Tel: +49 89 78080

Web: http://www.daiichi-sankyo.eu/

Company description

Germany is the European basis for DAIICHI SANKYO. Business activities here started in 1990, when former Sankyo acquired the Munich based Luitpoldwerke (main product: Mobilat). Today the European and German headquarters of DAIICHI SANKYO are located in Munich-Obersendling. From here about 350 DAIICHISANKYO-employees manage operations in twelve European countries, including big markets like France, Italy, UK and Spain. From Munich the company also directs 380 medical representatives working all over Germany, the total number of employees in Germany is 1100.

Germany and Europe play an important and increasing role at DAIICHI SANKYO group. Sales in Europe in the last Fiscal Year 2009/2010 (31rd of March) increased by more than 17 percent to 574 million Euro and accounted for more than 12 percent of the groups total revenues. Sales including the European activities of the Indian generic drug company Ranbaxy, in which DAIICHI SANKYO holds a majority stake, accumulated to nearly 760 million Euro. The business in Germany itself increased by 10 percent to sales of 77 million Euro.

Pfaffenhofen Manufacturing Plant
60 kilometers north of Munich, in Pfaffenhofen, is one of DAIICHI SANKYOs global manufacturing plants located. With about 400 employees it is the only European plant of DAIICHI SANKYO producing bulk and finished pharmaceutical goods. And it is the only “global” DAIICHI SANKYO plant outside Japan. Approximately 70 per cent of DAIICHI SANKYO EUROPE´s turnover is produced or handled via the Pfaffenhofen plant, the products are being exported into 50 countries all over the world.

In 2007 a state-of-the-art facility for solids manufacturing and packaging was inaugurated in Pfaffenhofen. The investment was 25 million Euro in total. Currently the manufacturing capacity is going to be doubled from 2 to 4 million tablets per year.
At the beginning of 2010 Pfaffenhofen was being inspected by the US Food and Drug Administration (FDA) for the third time in ten years. The inspectors of the authority had no complains and certificated the plant with best results. That is exceptional and a sign of the high quality standard of the plant.

U3 Pharma
In 2008 DAIICHI SANKYO acquired the biotech company U3 Pharma for 150 million Euro. U3 Pharma is located in Martinsried in the southern parts of Munich and is specialised on oncology research. The company was founded by Prof. Axel Ullrich, a highly respected Director of the German Max Planck Institute and famous Biotech-entrepreneur. Currently more than 30 employees, most of them biotech-scientists, are working at U3 Pharma on next generation oncology compounds.

Cooperations
DAIICHI SANKYO has several cooperations in the field of antibody therapies with the well known biotech company Morphosys from Martinsried (Munich). Last year the company additionally signed an agreement with the Swedish BioInvent for the discovery and development of therapeutic antibodies. BioInvent also works with U3 Pharma.

Products and services

Efient, Sefikar, Olmetec, Evista, Mevalotin, Podomefex, Lopresor, Lomir/Icaz

filterProfiles

Find a company:







Jobs from Indeed
LATEST ISSUE

DOWNLOAD


X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: